Malaria Research and Treatment / 2017 / Article / Tab 2

Research Article

Long-Term Prophylaxis and Pharmacokinetic Evaluation of Intramuscular Nano- and Microparticle Decoquinate in Mice Infected with P. berghei Sporozoites

Table 2

Main pharmacokinetic parameters of decoquinate in oily suspension with nano- and microparticle following single intramuscular injection at 120 mg/kg dose level in mice plasma ( = 2-3).

Main PK parameters following IM injectionNano-DQ (0.43 µm)
plasma
CV%Micro-DQ (8.31 µm)
plasma
CV%

(ng/ml)36.58 ± 3.569.7445.35 ± 8.0917.84
(hr)3.52 ± 0.133.823.22 ± 0.9027.86
(ng⋅hr/ml)10,385 ± 4053.9118,311 ± 9265.06
(hr)4.84 ± 0.7114.613.24 ± 1.5146.59
(hr)751.01 ± 28.723.821,444.90 ± 118.568.21
Vss/F (L/kg)12,155.69 ± 844.546.9513,403.78 ± 447.673.34
CL/F (L/hr/kg)11.56 ± 0.453.916.57 ± 0.324.84
Minimum inhibitory concentration (MIC) (ng/ml)5.12 ± 0.183.515.12 ± 0.183.51
> MIC (hr)624.25 ± 60.74
(3.72 weeks)
9.731375.00 ± 50.57
(8.18 weeks)
3.68

Value was calculated based on full causal prophylaxis effect for 8 weeks. IM: intramuscular; DQ: decoquinate; CV: coefficient of variation.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.